Loading
A phase 2 trial of Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by STCube, Inc., now recruiting.
Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07306624 by STCube, Inc., with 62 participants planned, started 2026-01-10 and due to reach its primary completion in 2027-08-31. Interventions recorded: Nelmastobart and Docetaxel. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares STCube, Cytotoxic chemotherapy.
Shares Docetaxel, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.